¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå ¼ºÀå ¹× µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀåÀº 2030³â±îÁö ¿¬Æò±Õ 33.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 29¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±¤¹üÀ§ÇÏ°í º¹ÀâÇÑ µ¥ÀÌÅÍ ¼¼Æ® °ü¸®¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ¹Ì±¹ ÀÇ·á ¿µ»ó AI ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 9¿ù Ű³×Ƽī´Â °í±Þ ¾ÆÅ°ÅØÃ³¿¡ ÅëÇÕµÈ ´ë±Ô¸ð ¾ð¾î ¸ðµ¨(LLM)À» ¹ßÇ¥Çß½À´Ï´Ù. À̸¦ ÅëÇØ »ç¿ëÀÚ´Â ¿ÜºÎ API È£Ãâ ¾øÀ̵µ ±¸Á¶ÈµÈ µ¥ÀÌÅÍ¿¡¼ ÀÚ¿¬¾î¸¦ »ç¿ëÇÏ¿© ½Ç½Ã°£ ¾ÖµåȤ µ¥ÀÌÅÍ ºÐ¼®À» ¼öÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ´Â °í°´ ȯ°æ ³»¿¡ ¸Ó¹°·¯ ÆÛºí¸¯ LLM°ú Â÷º°ÈµË´Ï´Ù. À̹ø ¹ßÇ¥´Â OpenAI¿ÍÀÇ ÅëÇÕÀ» À§ÇØ KineticaÀÇ ºÐ¼® µ¥ÀÌÅͺ£À̽º¸¦ ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.
ÇコÄÉ¾î ºÐ¾ß¿¡¼ ÀΰøÁö´É ±â¹Ý ±â¼úÀÇ ÅëÇÕÀ» ÁöÁöÇÏ´Â Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ¹Ì±¹ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 2¿ù ¹Ì±¹ Á¶´Þû(GSA)Àº ÀÇ·áÀÇ ÁúÀ» Çâ»ó½Ã۱â À§ÇØ ¿¬¹æ Á¤ºÎ ±â°ü¿¡ ´Ù¾çÇÑ ¼Ö·ç¼ÇÀ» Àå·ÁÇÏ´Â ´ëȸÀÎ 'Applied AI Healthcare Challenge'¸¦ ½ÃÀÛÇß½À´Ï´Ù. ÀÌ Ã§¸°Áö´Â AI ±â¼úÀ» Ȱ¿ëÇÏ¿© Á¤½Å °Ç°, Áßµ¶, °øÆò¼º, °ø±Þ¸Á ¾ÈÀü, ¾Ï ŽÁö µîÀ» ´Ù·ç°í ÀÖÀ¸¸ç, Challenge.gov ¹× ¿ì¼ö¼º ¼¾ÅÍ¿Í Çù·ÂÇÏ¿© Çõ½Å°ú °³¹æÇü °úÇÐÀÇ ÇØ Âü¿©¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¹Ì±¹ ÀÇ·á¿ë À̹Ì¡ AI ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®:
- ±â¼úº°·Î´Â µö·¯´× ºÐ¾ß°¡ 2023³â 58.6%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ÈÆ·Ã ¸ñÀûÀÇ ±¤¹üÀ§ÇÑ ÀÇ·á ¿µ»ó µ¥ÀÌÅÍ ¼¼Æ®ÀÇ °¡¿ë¼ºÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Á¤±³ÇÑ µö·¯´× ¸ðµ¨ °³¹ßÀÌ ¿ëÀÌÇØÁ³±â ¶§¹®À¸·Î ºÐ¼®µË´Ï´Ù. ¹Ý¸é, ÀÚ¿¬¾î ó¸®(NLP) ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ÀÀ¿ë ºÐ¾ßº°·Î º¸¸é, ½Å°æÇÐ ºÐ¾ß°¡ 2023³â 37.9%ÀÇ ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ´õ ³ªÀº ȯÀÚ Ä¡·á¸¦ Á¦°øÇÏ°í ´õ ³ôÀº Á¤È®µµ¿Í È¿À²¼ºÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ½Å°æÇÐ ºÐ¾ß¿¡¼ AIÀÇ »ç¿ëÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. À¯¹æ °ËÁø ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ¾ç½Äº°·Î´Â CT ½ºÄµ ºÐ¾ß°¡ 2023³â 35.2%ÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇßÀ¸¸ç, X¼± ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ÃÖÁ¾ ¿ëµµ¸¦ ±âÁØÀ¸·Î º´¿ø ºÎ¹®Àº 2023³â 52.8%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» Àå¾ÇÇÏ°í ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- 2023³â 9¿ù, ¸¶ÀÌÅ©·Î¼ÒÇÁÆ®¿Í ÇコÄÉ¾î ±â¼ú ±â¾÷ Paige´Â µðÁöÅÐ º´¸®ÇÐ ¹× Á¾¾çÇÐÀ» À§ÇÑ °¡Àå ±¤¹üÀ§ÇÑ À̹ÌÁö ±â¹Ý ÀΰøÁö´É(AI) ¸ðµ¨À» Àü ¼¼°èÀûÀ¸·Î °³¹ßÇϱâ À§ÇØ Çù·ÂÇϱâ·Î Çß½À´Ï´Ù. ÀÌ ±¸»óÀº ¾Ï Áø´Ü¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ȯÀÚ Ä¡·á¸¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ ÆÄÆ®³Ê½ÊÀº ÀÌ ºÐ¾ßÀÇ Áøº¸¸¦ Ȱ¿ëÇÏ¿© ¾Ï Áø´Ü ¹× Ä¡·á ¹æ¹ýÀ» º¯È½ÃŰ°í ±Ã±ØÀûÀ¸·Î ÀÇ·á ±â¼ú ¹ßÀü¿¡ ±â¿©ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
- PESTEL ºÐ¼®
Á¦4Àå ¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ±â¼ú ÃßÁ¤¡¤µ¿Ç⠺м®
- ±â¼ú ½ÃÀå Á¡À¯À², 2023³â & 2030³â
- ¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå, ±â¼ú Àü¸Á
- ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
Á¦5Àå ¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â & 2030³â
- ¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå, ¿ëµµ Àü¸Á
- ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
Á¦6Àå ¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ¸ð´Þ¸®Æ¼ ÃßÁ¤¡¤µ¿Ç⠺м®
- ¸ð´Þ¸®Æ¼ ½ÃÀå Á¡À¯À², 2023³â & 2030³â
- ¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå, ¸ð´Þ¸®Æ¼ Àü¸Á
- ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
Á¦7Àå ¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ÃÖÁ¾ ¿ëµµ ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
- ¹Ì±¹ÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå, ÃÖÁ¾ ¿ëµµ Àü¸Á
- ½ÃÀå ±Ô¸ð, ¿¹Ãø ¹× µ¿Ç⠺м®, 2018-2030³â
Á¦8Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)
- º¥´õ ±¸µµ
- ±â¾÷ °³¿ä
- GE HealthCare
- Microsoft
- Digital Diagnostics Inc.
- TEMPUS
- Butterfly Network, Inc.
- Advanced Micro Devices, Inc.
- HeartFlow, Inc.
- Enlitic, Inc.
- Canon Medical Systems USA, Inc.
- Viz.ai, Inc.
- EchoNous, Inc.
- HeartVista Inc.
- Exo Imaging, Inc
- NANO-X IMAGING LTD
LSH 24.03.27
U.S. AI in Medical Imaging Market Growth & Trends:
The U.S. AI in medical imaging market is anticipated to reach USD 2.93 billion by 2030 and is anticipated to expand at a CAGR of 33.2% during the forecast period, according to a new report by Grand View Research, Inc. The increasing demand for managing extensive and complex datasets are the major factors contributing to the U.S. artificial intelligence (AI) in medical imaging market growth. For instance, in September 2023, Kinetica announced a Large Language Model (LLM) integrated with its advanced architecture. It enables users to conduct real-time, ad-hoc data analysis using natural language on structured data without needing external API calls. Data remains within the customer's environment, differentiating it from public LLMs. This announcement builds on Kinetica's analytic database to integrate with OpenAI.
The rising government initiatives endorsing the integration of artificial intelligence-based technologies in healthcare, is projected to drive the demand for AI in medical imaging market in the U.S. during the forecast period. For instance, in February 2023, the U.S. General Services Administration (GSA) initiated the Applied AI Healthcare Challenge, a competition encouraging diverse solutions for federal agencies to enhance medical care quality. This challenge addresses mental health, addiction, equity, supply chain safety, and cancer detection through AI technologies, fostering innovation and participation in the Year of Open Science in collaboration with Challenge.gov and the Centers of Excellence.
U.S. AI in Medical Imaging Market Report Highlights:
- Based on technology, the deep learning segment dominated the market in terms of revenue share of 58.6% in 2023 owing to the growing availability of extensive medical imaging datasets for training purposes facilitates the development of sophisticated deep learning models. On the other hand, the natural language processing (NLP) segment is expected to grow at the fastest CAGR over the forecast period
- Based on application, the neurology segment dominated the market in terms of revenue share of 37.9% in 2023 owing to the increased use of AI in neurology, as it provides better patient care and enables higher accuracy and high efficiency. The breast screening segment is expected to grow at the fastest CAGR over the forecast period
- Based on modalities, the CT scan segment dominated the market with 35.2% share in 2023 due to the higher standard imaging method for many clinical results. The X-Ray segment is expected to grow at the fastest CAGR over the forecast period
- Based on end use, the hospitals segment dominated the market with 52.8% share in 2023 and is expected to grow at the fastest CAGR over the forecast period, the growth is anticipated as patients prefer hospitals for the treatment process in terms of convenience and various product offerings in one place.
- In September 2023, Microsoft and healthcare technology company Paige collaborated to develop the most extensive image-based artificial intelligence (AI) models for digital pathology and oncology globally. This initiative seeks to revolutionize cancer diagnosis and enhance patient care. Leveraging advancements in the field, the partnership aspires to create a transformative impact on how cancer is diagnosed and treated, ultimately contributing to advancements in healthcare technology
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Technology
- 1.2.2. Application
- 1.2.3. Modalities
- 1.2.4. End use
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Volume price analysis (Model 2)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Technology outlook
- 2.2.2. Application outlook
- 2.2.3. Modalities outlook
- 2.2.4. End use outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Artificial Intelligence in Medical Imaging Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. U.S. Artificial Intelligence in Medical Imaging Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social Landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal Landscape
Chapter 4. U.S. Artificial Intelligence in Medical Imaging Market: Technology Estimates & Trend Analysis
- 4.1. Technology Market Share, 2023 & 2030
- 4.2. U.S. Artificial Intelligence in Medical Imaging Market by Technology Outlook
- 4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.3.1. Deep learning
- 4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.3.2. Natural language processing
- 4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.3.3. Others
- 4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Artificial Intelligence in Medical Imaging Market: Application Estimates & Trend Analysis
- 5.1. Treatment Market Share, 2023 & 2030
- 5.2. U.S. Artificial Intelligence in Medical Imaging Market by Application Outlook
- 5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.3.1. Neurology
- 5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.2. Respiratory and pulmonary
- 5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.3. Cardiology
- 5.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.4. Breast screening
- 5.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.5. Orthopedics
- 5.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.6. Others
- 5.3.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Artificial Intelligence in Medical Imaging Market: Modalities Estimates & Trend Analysis
- 6.1. Application Market Share, 2023 & 2030
- 6.2. U.S. Artificial Intelligence in Medical Imaging Market by Modalities Outlook
- 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.3.1. CT scan
- 6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
- 6.3.2. Magnetic resonance imaging (MRI)
- 6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.3. X-Rays
- 6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.4. Ultrasound
- 6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.5. Nuclear imaging
- 6.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Artificial Intelligence in Medical Imaging Market: End-Use Estimates & Trend Analysis
- 7.1. End-Use Market Share, 2023 & 2030
- 7.2. U.S. Artificial Intelligence in Medical Imaging Market by End-Use Outlook
- 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 7.3.1. Hospitals
- 7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
- 7.3.2. Diagnostic Imaging Centers
- 7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.3. Others
- 7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key companies heat map analysis, 2023
- 8.4. Company Profiles
- 8.4.1. GE HealthCare
- 8.4.1.1. Company overview
- 8.4.1.2. Financial performance
- 8.4.1.3. Product benchmarking
- 8.4.1.4. Strategic initiatives
- 8.4.2. Microsoft
- 8.4.2.1. Company overview
- 8.4.2.2. Financial performance
- 8.4.2.3. Product benchmarking
- 8.4.2.4. Strategic initiatives
- 8.4.3. Digital Diagnostics Inc.
- 8.4.3.1. Company overview
- 8.4.3.2. Financial performance
- 8.4.3.3. Product benchmarking
- 8.4.3.4. Strategic initiatives
- 8.4.4. TEMPUS
- 8.4.4.1. Company overview
- 8.4.4.2. Financial performance
- 8.4.4.3. Product benchmarking
- 8.4.4.4. Strategic initiatives
- 8.4.5. Butterfly Network, Inc.
- 8.4.5.1. Company overview
- 8.4.5.2. Financial performance
- 8.4.5.3. Product benchmarking
- 8.4.5.4. Strategic initiatives
- 8.4.6. Advanced Micro Devices, Inc.
- 8.4.6.1. Company overview
- 8.4.6.2. Financial performance
- 8.4.6.3. Product benchmarking
- 8.4.6.4. Strategic initiatives
- 8.4.7. HeartFlow, Inc.
- 8.4.7.1. Company overview
- 8.4.7.2. Financial performance
- 8.4.7.3. Product benchmarking
- 8.4.7.4. Strategic initiatives
- 8.4.8. Enlitic, Inc.
- 8.4.8.1. Company overview
- 8.4.8.2. Financial performance
- 8.4.8.3. Product benchmarking
- 8.4.8.4. Strategic initiatives
- 8.4.9. Canon Medical Systems USA, Inc.
- 8.4.9.1. Company overview
- 8.4.9.2. Financial performance
- 8.4.9.3. Product benchmarking
- 8.4.9.4. Strategic initiatives
- 8.4.10. Viz.ai, Inc.
- 8.4.10.1. Company overview
- 8.4.10.2. Financial performance
- 8.4.10.3. Product benchmarking
- 8.4.10.4. Strategic initiatives
- 8.4.11. EchoNous, Inc.
- 8.4.11.1. Company overview
- 8.4.11.2. Financial performance
- 8.4.11.3. Product benchmarking
- 8.4.11.4. Strategic initiatives
- 8.4.12. HeartVista Inc.
- 8.4.12.1. Company overview
- 8.4.12.2. Financial performance
- 8.4.12.3. Product benchmarking
- 8.4.12.4. Strategic initiatives
- 8.4.13. Exo Imaging, Inc
- 8.4.13.1. Company overview
- 8.4.13.2. Financial performance
- 8.4.13.3. Product benchmarking
- 8.4.13.4. Strategic initiatives
- 8.4.14. NANO-X IMAGING LTD
- 8.4.14.1. Company overview
- 8.4.14.2. Financial performance
- 8.4.14.3. Product benchmarking
- 8.4.14.4. Strategic initiatives